MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States
Public ClinicalTrials.gov record NCT00121108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study of MEDI-524 (Motavizumab), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
MI-CP117 was a Phase 3, randomized, double-blind, placebo-controlled trial designed to determine if motavizumab is more effective than placebo in reducing RSV hospitalization in otherwise healthy Native American Infants in the Southwestern United States during their first RSV season.
Study identification
- NCT ID
- NCT00121108
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,127 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 0 Months to 6 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2004 (Actual)
- Primary completion
- Dec 27, 2010 (Actual)
- Completion
- Dec 27, 2010 (Actual)
- Last update posted
- Jan 5, 2022
2004 – 2010
United States locations
- U.S. sites
- 12
- U.S. states
- 3
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Chinle | Arizona | — | — |
| Research Site | Cibecue | Arizona | — | — |
| Research Site | Fort Definace | Arizona | — | — |
| Research Site | San Carlos | Arizona | — | — |
| Research Site | Tuba City | Arizona | — | — |
| Research Site | Whiteriver | Arizona | — | — |
| Research Site | Winslow | Arizona | — | — |
| Research Site | Baltimore | Maryland | 21205 | — |
| Research Site | Bloomfield | New Mexico | — | — |
| Research Site | Crownpoint | New Mexico | — | — |
| Research Site | Gallup | New Mexico | — | — |
| Research Site | Shiprock | New Mexico | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00121108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2022 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00121108 live on ClinicalTrials.gov.